Reprinted from hcrenewal.blogspot.com
Not to bury the lede, I think it can, but it will be a lot harder than the talking heads on television predict.
There is no country in the world better prepared than the United States to deal with this. We have the best public health infrastructure and the best doctors in the world.
However, at least the statistics say compared to other developed countries, US processes and outcomes are at best mediocre using the best of some admittedly flawed metrics (look here), yet our costs are much higher than those of comparable countries. Furthermore, on Health Care Renewal we have been connecting the dots among severe problems with cost, quality and access on one hand, and huge problems with concentration and abuse of power, enabled by leadership of health care organizations that is ill-informed, incompetent, unsympathetic or hostile to health care professionals' values, self-interested, conflicted, dishonest, or even corrupt and governance that fails to foster transparency, accountability, ethics and honesty.
Financialization of Pharmaceutical and Biotechnology Companies
George W Merck famously said,
We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we have remembered it, the larger they have been.
In the pharmaceutical industry, the era of George W Merck is over. The failure to have access to an effective Ebola virus vaccine exemplifies how things have changed.
If we were to have an effective Ebola virus vaccine, we could have likely used it to vaccinate health care workers and contacts of infected patients and likely thus halt the epidemic early.
A story in Modern Healthcare suggested that now many of the big experts on Ebola and public health are concluding having a vaccine available would be very helpful,
As West Africa's Ebola outbreak continues to rage, some experts are coming to the conclusion that it may take large amounts of vaccines and maybe even drugs -- all still experimental and in short supply -- to bring the outbreak under control.